article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006. Amsterdam: Gupta Strategists; 2019.

article thumbnail

After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient

Clarivate

2: Patient flows for Humira versus generic competitors in France post-LOE Source: Clarivate Patient Data Intelligence “What we’re seeing here is the resilience of complex blockbuster biologics,” said Nicole Parisi, Clarivate Lead Business Analyst. In the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

pharmaphorum

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50

Pharma 87
article thumbnail

Bayer plans to scale back women’s health R&D

Pharmaceutical Technology

Following Bayer’s takeover of Schering Healthcare in 2006, where it inherited the oral contraceptive Yasmin (ethinyl estradiol + drospirenone) and the intrauterine device Mirena (levonorgestrel-releasing system), the German drugmaker has become one of the world’s leading pharmaceutical specialists in women’s health.

article thumbnail

Making an Impact During Disease Awareness Days, Weeks, and Months

PM360

In 2006, Facebook boomed in mainstream popularity and MySpace was one of the most visited websites. In a world that is so driven by metrics, data, and ROI, it’s easy to write off awareness campaigns as unsuccessful or unimpactful if they aren’t driving sales or directly leading to better outcomes.

Media 92
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. million in sales by 2032. percent sales expected in 2032 within the seven major markets.

article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

Lee currently leads the Commercial Innovation Group at Syneos Health. Until July of 2006, Mr. Baxter was SVP, R&D Finance and Operations, of GlaxoSmithKline (GSK). We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities.